Mylan's Acquisition Gambit

The generic-drug maker's debt-fueled merger is taking the company to the next level.

UNFRIENDLY CREDIT MARKETS BE DAMNED: Sometimes a company has to borrow money to make money.

Just look at U.S. generic-drug maker Mylan. The company took on a big chunk of debt to fund the lion's share of its recent $6.8 billion purchase of the much bigger generic-drug business of Germany's Merck KGaA, one of the oldest drug and chemical companies...